At a glance
ClinicalIndex Comparison RecordPhase 2Active· 216 target
Drug / intervention
AK127 in combination with AK112drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK112 in Patients With Advanced Malignant Tumors
In Brief
A Phase 2 clinical trial evaluating AK127 in combination with AK112 for Advanced Solid Tumors. Active but no longer recruiting, targeting 216 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2Active
202420252026
First PostedJul 2023
Enrollment StartOct 2023
Primary CompletionMay 2026
TodayJul 2026
Study CompletionAug 2026
First PostedJul 19, 2023
Enrollment StartOct 16, 2023
Primary CompletionMay 1, 2026
Study CompletionAug 15, 2026
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 2.9 years ago
Interventions
AK127 in combination with AK112drug
AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years